Verastem Says Median Overall Survival Not Reached in Partner's Phase 1/2 Pancreatic Cancer Study; Shares Fall
MT Newswires Live
Oct 21, 2025
Verastem (VSTM) said Sunday that results from partner GenFleet Therapeutics' phase 1/2 study in China of GFH375 in patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma did not meet the median overall survival at data cutoff.
Among 59 heavily pre-treated patients, 40.7% achieved overall response rate at the 600 milligram daily dose, 91.5% experienced tumor reduction, and the disease control rate was 96.7%, the company said.
The safety profile was consistent with previous findings indicating manageable tolerability with a 4% discontinuation rate due to adverse events, it said.
Verastem shares were down 11% in recent Monday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.